EZH2 and systemic lupus erythematosus: Thus, we propose that excessive EZH2 contributes to the pathogenesis of SLE at least partly through promoting the activation of IFN-I signaling pathway and EZH2 inhibitor may be used to treat IFN-I-driven SLE manifestations.